Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial…
Biotechnology
US, New York [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Anavex Life Sciences Corp.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2023 | -0.6000 | -0.630 | 0 | 0 | -47 | -50 | -55 | 0 | -55 | 0 | 12 | 0 |
| 2024 | -0.5200 | -0.543 | 0 | 9 | -43 | -43 | 0 | 0 | -52 | 0 | 11 | 0 |
| 2025 | - | -0.603 | - | 14 | - | -53 | - | 0 | - | 0 | - | 0 |
| 2026 | - | 3.F3X/td> | - | 3.F3X/td> | - | 3.F3X/td> | - | 3.F31/td> | - | 3.F31 | - | 3.F31 |
| 2027 | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F4X/td> | - | 2.F41/td> | - | 2.F41 | - | 2.F41 |
| 2028 | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F5X/td> | - | 1.F51/td> | - | 1.F51 | - | 1.F51 |
| 2029 | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F6X/td> | - | 0.F61/td> | - | 0.F61 | - | 0.F61 |